Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM CVE:GPH TSE:GXE NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.26-2.3%$1.22$0.46▼$7.49$6.74M-0.110.27 million shs57,049 shsGPHGraphite OneC$1.02+5.2%C$0.83C$0.64▼C$1.14C$103.28M1.0289,450 shs189,288 shsGXEGear EnergyC$0.50C$0.45▼C$0.80C$126.52M3.52585,822 shs1.03 million shsVIRVir Biotechnology$4.30-1.1%$5.30$4.25▼$14.45$597.34M1.181.05 million shs1.54 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group0.00%-8.03%+35.48%+46.36%-54.01%GPHGraphite One0.00%-4.67%+52.24%+30.77%+20.00%GXEGear Energy0.00%0.00%0.00%0.00%-26.15%VIRVir Biotechnology0.00%-14.51%-27.49%-15.52%-48.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.2293 of 5 stars0.05.00.00.01.51.70.6GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AGXEGear EnergyN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.7975 of 5 stars3.41.00.00.02.13.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/AGPHGraphite One 0.00N/AN/AN/AGXEGear Energy 2.00HoldN/AN/AVIRVir Biotechnology 2.88Moderate Buy$30.25603.49% UpsideCurrent Analyst Ratings BreakdownLatest VIR, APM, GXE, and GPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform7/11/2025VIRVir BiotechnologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$12.005/22/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.005/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K15.68N/AN/A$2.20 per share0.57GPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AGXEGear EnergyC$134.93M0.00N/A540.00C$0.93 per share0.00VIRVir Biotechnology$74.21M8.05N/AN/A$6.82 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/AGPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AGXEGear EnergyC$13.02MC$0.0510.39N/AN/A8.53%5.08%4.84%N/AVIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%N/ALatest VIR, APM, GXE, and GPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AGXEGear EnergyC$0.0611.46%N/A120.00%N/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22GPHGraphite One0.021.090.33GXEGear Energy6.271.200.56VIRVir BiotechnologyN/A7.016.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%GPHGraphite One0.07%GXEGear Energy2.42%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%GPHGraphite One28.81%GXEGear Energy7.62%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableGXEGear Energy1,310263.58 millionN/ANot OptionableVIRVir Biotechnology580138.92 million116.69 millionOptionableVIR, APM, GXE, and GPH HeadlinesRecent News About These CompaniesRaymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)August 9 at 11:38 PM | theglobeandmail.comShort Interest in Vir Biotechnology, Inc. (NASDAQ:VIR) Rises By 50.7%August 9 at 2:43 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak EarningsAugust 8 at 11:22 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 11.1% After Earnings MissAugust 8 at 3:09 AM | americanbankingnews.comVir Biotechnology Reports Q2 2025 Financial ResultsAugust 7 at 4:43 AM | msn.comVir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentumAugust 7 at 4:43 AM | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Short Interest UpdateAugust 7 at 2:26 AM | marketbeat.comVir (VIR) Q2 Revenue Drops 61%August 7 at 2:00 AM | fool.comVir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comVir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | businesswire.comVir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis DeltaAugust 6, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in StockAugust 5, 2025 | marketbeat.comBrokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $30.25August 4, 2025 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 1, 2025 | marketbeat.comVir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical SetbacksJuly 31, 2025 | genengnews.comGVir Biotechnology (VIR) Projected to Post Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comVir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis DeltaJuly 31, 2025 | businesswire.comAllianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31, 2025 | marketbeat.comVictory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseJuly 30, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyBy Leo Miller | July 16, 2025View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyA New AI Tailwind Could Come to Boost Taiwan Semiconductor StockBy Gabriel Osorio-Mazilli | August 5, 2025View A New AI Tailwind Could Come to Boost Taiwan Semiconductor StockVIR, APM, GXE, and GPH Company DescriptionsAptorum Group NASDAQ:APM$1.26 -0.03 (-2.33%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.79%) As of 08/8/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Graphite One CVE:GPHC$1.02 +0.05 (+5.15%) As of 08/8/2025 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Gear Energy TSE:GXEGear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.Vir Biotechnology NASDAQ:VIR$4.30 -0.05 (-1.15%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.30 0.00 (-0.12%) As of 08/8/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
